Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2010 Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation Nat Med 2010; 16:897-902
2. 2010 Control of immune response by amino acid metabolism Immunol Rev 2010; 236:243-64.
3. 2009 IDO mediates TLR9-driven protection from experimental autoimmune diabetes J Immunol 2009; 183:6303-13.
4. 2009 Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med 2009; 206:2511-26.
5. 2009 TGF-b and kynurenines as the key to infectious tolerance Trends Mol Med 2009; 15:41-49.
6. 2008 Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008; 451(7175):211-5.
7. 2008 SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis Proc Natl Acad Sci U S A 2008; 105:20828-33.
8. 2008 Cutting edge: Autocrine TGF-b sustains default tolerogenesis by IDO-competent dendritic cells J Immunol 2008; 181;5194-5198.
9. 2007 Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13:579-586
10. 2007 IDO and regulatory T cells: a role for reverse signaling and non-canonical NF-kB activation Nat Rev Immunol 2007; 7:817-823.
11. 2006 Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 2006; 177:130-137.
12. 2006 The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor z-chain and induce a regulatory phenotype in naïve T cells. J Immunol 2006; 176:6752-6761.
13. 2005 Towards the identification of a tolerogenic signature in IDO-competent dendritic cells Blood 2005; 107:2846-2854
14. 2005 Cutting Edge: Silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant J Immunol 2005; 174:6582-6586.
15. 2005 CD40 ligation prevents onset of tolerogenic properties in human dendritic cells treated with CTLA-4-Ig Microbes Infect 2005; 7:1040-1048
16. 2005 Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. Eur J Immunol 2005; 35:3111-3118
17. 2004 CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86 Nat Immunol 2004; 5:1134-1142.
18. 2004 CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice J Exp Med 2004; 200:1051-1062
19. 2003 A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice J Exp Med 2003; 198:153-160.
20. 2003 Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24:242-248.
21. 2003 Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation. J Immunol 2003; 171:2581-2587.
22. 2003 CTLA-4, T helper lymphocytes and dendritic cells: an internal perspective of T-cell homeostasis Trends Mol Med 2003; 9:133-135
23. 2003 Modulation of tryptophan catabolism by regulatory T cells Nat Immunol 2003; 4:1206-1212.
24. 2002 CTLA-4Ig regulates tryptophan catabolism in vivo Nat Immunol 2002; 3:1097-1101.
25. 2001 IL-6 inhibits the tolerogenic function of CD8a+ dendritic cells expressing indoleamine 2,3-dioxygenase J Immunol 2001; 167:708-714.
26. 1998 IL-12 acts directly on DC to promote nuclear localization of NF-kB and primes DC for IL-12 production Immunity 1998; 9:315-323.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.